PAVmed Inc logo

PAVmed Inc Investor Relations Material

PAVmed Inc. holds interests in various medical device technologies at various stages of development. Its initial pipeline includes: carPIX, a technology that transforms the humble stethoscope into a highly effective imaging tool; EsoGuard/EsoCheck, a novel, multi-marker screening test for esophageal cancer and Barrett's esophagus; PortIO, an implantable intraosseous vascular access device that could revolutionize the way patients needing vascular access are treated.

NextCath, a revolutionary self-anchoring catheter technology based on an internally developed platform that eliminates the need for sutures or tissue adhesives to secure a catheter to the body; and NextVessel, which is being developed by NextCath Inc., and is designed to provide early detection of coronary atherosclerosis and other vascular conditions. PAVmed Inc. was founded in 2014 and is headquartered in New York, New York

Latest company events

Ticker symbol



United States of America

About the company

Investor Relations Page

Dig deeper into the PAVmed Inc fundamentals on Quartr.

  • Skip straight to the Q&A session
  • Receive notifications about new events
  • Connect the financial calender on your phone
  • Figure out why the stock is up or down
  • Read the transcripts or scroll the deck
  • Access earnings or press releases
App store link
Android play link
Quartr app screenshot